Early View Original research article Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19–a randomised double-blinded placebo-controlled trial Pradeesh Sivapalan, Charlotte Suppli Ulrik, Therese Sophie Lapperre, Rasmus Dahlin Bojesen, Josefin Eklöf, Andrea Browatzki, Jon Torgny Wilcke, Vibeke Gottlieb, Kjell Erik Julius Håkansson, Casper Tidemandsen, Oliver Tupper, Howraman Meteran, Christina Bergsøe, Eva Brøndum, Uffe Bodtger, Daniel Bech Rasmussen, Sidse Graff Jensen, Lars Pedersen, Alexander Jordan, Helene Priemé, Christian Søborg, Ida E. Steffensen, Dorthe Høgsberg, Tobias Wirenfeldt Klausen, Martin Steen Frydland, Peter Lange, Asger Sverrild, Muhzda Ghanizada, Filip Krag Knop, Tor Biering-Sørensen, Jens D. Lundgren, Jens-Ulrik Stæhr Jensen, Please cite this article as: Sivapalan P, Suppli Ulrik C, Sophie Lapperre T, et al. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19–a randomised double-blinded placebo-controlled trial. Eur Respir J 2021; in press (https://doi.org/10.1183/13993003.00752-2021). This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contactt
[email protected] Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19 - a randomised double- blinded placebo-controlled trial by the ProPAC-COVID study group* *A complete list of members in the Proactive Protection with Azithromycin and hydroxy- Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID) Study Group is provided in Supplementary Appendix 3.